Cypher Sirolimus-Eluting Coronary Stent Had Similar Results to,,,Bypass Surgery and Better Outcomes Than Bare Metal Stents in,,,Subgroup Analysis of Diabetic Patients With Multivessel Coronary,,,Disease
BARCELONA, Spain, May 22, 2007 /PRNewswire/ -- A three-year
follow-up subset analysis presented today as a late-breaking
clinical trial at EuroPCR 2007 showed that the CYPHER(R)
Sirolimus-eluting Coronary Stent had results comparable to coronary
artery bypass grafting (CABG or bypass surgery) and better outcomes
than bare metal stents (BMS) in diabetic patients with blockages in
two or more coronary arteries.
The CYPHER(R) Stent results in the diabetic population of the
ARTS II Study showed no significant difference in major adverse
cardiac and cerebrovascular events (MACCE) compared to the CABG arm
of the ARTS I Study (27.7 percent versus 17.7 percent,
respectively; p = 0.10). In addition, the analysis showed that the
CYPHER(R) Stent performed significantly better than the BMS arm of
the ARTS I Study, as 47.3 percent of the patients who received a
BMS experienced a MACCE event after three years (p < 0.001).
These findings are significant as MACCE -- comprised of death,
stroke, myocardial infarction (heart attack) and the need for
repeat revascularization (re-treatment) of the blocked artery --
was the primary endpoint of the ARTS II Study.
Sponsored by Cordis Corporation, the ARTS II Study was designed
to determine whether the clinical and cost-effectiveness outcomes
with the CYPHER(R) Stent in 607 patients with multivessel coronary
disease were non- inferior to the results obtained in the ARTS I
Study, which was conducted in 1997 and included 605 patients
treated with bypass surgery and 600 patients treated with a BMS. In
the diabetic subgroup analysis, investigators compared the findings
for the 159 diabetic patients in the ARTS II Study to those from
the ARTS I Study, which included 96 diabetic patients treated with
bypass surgery and 112 treated with a BMS. The risk profile of the
patients in the ARTS II Study was significantly higher Page: 1 2 3 4 Related medicine technology :1
. Cypher Sirolimus-eluting Coronary Stent Had Similar Results to
Bypass Surgery in Long-Term Study of Patients With Multi-Vessel
Coronary Artery Disease2
. Two-Year Patient Registry Results Support Safety and Efficacy of
Cypher Sirolimus-Eluting Coronary Stent in Real World Uses3
. New Study Suggests Better Patient Outcomes with CYPHER
Sirolimus-Eluting Coronary Stent than with Taxus Stent in
Real-World Clinical Settings4
. New Point-of-Care Methods to Measure Coronary and Cerebrovascular Risk5
. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease6
. BusinessWeek Article Highlights Promising Breakthrough Treatment
for Advanced Coronary Artery Disease7
. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by
Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who
Experienced a Recent Stroke8
. New Analysis of WHI Data Shows Reduced Levels of Coronary Artery
Calcification, a Predictor of Cardiovascular Events, in Women aged
50-59 taking Estrogen Therapy9
. Positive Results for Second-Generation Taxus Liberte Coronary Stent
System Highlighted in Journal of American College of Cardiology10
. Abbott Announces Positive Nine-Month Results From the Worlds First
Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent11
. Abbott Announces Continued Positive Results with Xience V
Everolimus Eluting Coronary Stent in Spirit Clinical Trials
(Date:8/28/2015)... y LONDRES, 28 de agosto de 2015 ... anunció hoy su participación en el Congreso de ... soluciones cardiológicas más recientes y novedosas, entre ellas ... conectan a las personas y la tecnología con ... a diagnosticar, guiar los tratamientos y permitir atención ...
(Date:8/28/2015)... August 28, 2015 The global ... USD 49.12 billion by 2020, growing at a CAGR ... new report by Grand View Research, Inc. Monitoring services ... 49.7% from 2014 to 2020. (Logo: ... along with rising incidences of chronic diseases such as ...
(Date:8/27/2015)... , Aug. 27, 2015 A recent study ... Knee Journal, compared the Arthrosurface HemiCAP® Wave implant, ... versus an "onlay" design implant for isolated patellofemoral ... in function and pain scores, none of the ... osteoarthritis (OA). However, 53% of the patients in ... Breaking Medicine Technology:Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 2Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 3Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 4Philips presenta nuevas soluciones cardiológicas integradas para desarrollar procedimientos menos invasivos 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... HeartWare International, Inc. (Nasdaq: HTWR ; ASX: ... support technologies that are revolutionizing the treatment of advanced ... scheduled to make an investor presentation at the 29th ... Time on Monday, January 10, 2011. The conference is ...
... MOUNTAIN VIEW, Calif., Jan. 4, 2011 MAP Pharmaceuticals, Inc. ... will present at the 29th Annual J.P. Morgan Healthcare Conference ... San Francisco. A live webcast of the ... MAP Pharmaceuticals, website at http://www.mappharma.com . A replay will ...Cached Medicine Technology:HeartWare to Present at the 29th Annual J.P. Morgan Healthcare Conference 2
(Date:8/28/2015)... ... 28, 2015 , ... SharkNinja, an innovative leader in the ... actress, Sofia Vergara, and unveil the Ninja® brand’s new coffee machine, the ... a variety of sizes and styles while achieving the perfect brew richness level ...
(Date:8/28/2015)... ... 28, 2015 , ... United Benefit Advisors (UBA), the nation’s ... as its newest Partner Firm. Founded in 1924 and headquartered in Pittsburgh, Pennsylvania, ... their goals. Within the past 10 years, TJS Insurance Group has emerged as ...
(Date:8/28/2015)... Knoxville, TN (PRWEB) , ... August 28, 2015 , ... ... surrounding the Centers for Medicare & Medicaid Services’ (CMS) proposal to mandate bundled ... 45-minute webinar , “Get Ready for Game Day: Comprehensive Care for Joint Replacement,” ...
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Santa Rosa ... to Work in Healthcare by Modern Healthcare. In the KLAS “2015 Midterm Performance Review: ... , “We believe the recognitions from Modern Healthcare and KLAS are directly related ...
(Date:8/27/2015)... Caicos Islands, BWI (PRWEB) , ... August 28, 2015 , ... ... for weddings. This award is added to an already impressive list of accolades ... Grace Bay was ranked as the #2 beach in the world by TripAdvisor, the ... Breaking Medicine News(10 mins):Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 2Health News:Sofia Vergara Partners With SharkNinja® To Launch The Ninja Coffee Bar™ 3Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 2Health News:TJS Insurance Group Is Latest Partner Firm To Join United Benefit Advisors 3Health News:PYA Offers Complimentary CCJR Webina — Game On 2Health News:PYA Offers Complimentary CCJR Webina — Game On 3Health News:Santa Rosa Consulting Recognized by Modern Healthcare as One of the Top 100 Best Places to Work and from KLAS Research with the Highest Rating for Go-Live Support 2Health News:Grace Bay Beach Acknowledged as a Top Caribbean Beach for Weddings 2
... in the recent years. But a new study has found ... took such vows. // ,The study also questions ... gauging how well they adhere to these pledges, reports foodconsumer.org. ... or written declarations to remain a virgin until marriage. ...
... in the arm for researchers of biological intelligence in the ... resemble a baby infant’s learning process, aided by it’s ... roboticists from Italy, France and Switzerland, is an ingenious effort ... similar manner of experimenting with objects available, and imbibing the ...
... the US it was found that the condition has fast ... disorder that is afflicting an estimated 300,000 U.S. schoolchildren, or ... estimate contraindicates with the estimate of 1 in every 2,000 ... about an argument as to whether the higher prevalence reflects ...
... as a beneficial and healthy activity. With the emphasis slowly, ... there’s nothing like a bit of gardening to rev up ... Institute at Northwestern Memorial Hospital in Chicago says that the ... when you bend down at your knees. "It's going to ...
... Syndrome or the shaking leg syndrome is a common type of ... their legs//. For the first time Europe has approved the drug ... and causes aches and pains. Statistics show that about 10% of ... was given by the European Medicines Agency. As of now it ...
... non-hormonal male contraceptive device that targets sperms, called Intra Vas ... study// involving 90 men. Men and women have long been ... this first male contraceptive to be marketed market may not ... place in Seattle, Washington and St. Paul, Minnesota, will bring ...Cached Medicine News:Health News:Teenagers Often Deny Taken ‘Virginity Pledges 2Health News:Burn Away Calories In Your Garden 2Health News:Non-Hormonal Male Contraceptive Based on Sperm Block Underway 2
The ALP method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of alkaline phosphatase activity in serum or plasma....
... Tm Bioscience introduces the Tag-It™ Cystic ... for cystic fibrosis genotyping. With validated performance ... assay will provide superior mutation coverage for ... aid to diagnosis in newborns. ,The ...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...
The Tag-It™ Cystic Fibrosis ASR reagents can be used by high complexity CLIA approved laboratories for detection of up to 70 mutations and 6 variants (polymorphisms) in the cystic fibrosis tran...Medicine Products: